Akèy › Kansè pwostat rezistan a kastasyon › Washington
Etid klinik pou Kansè pwostat rezistan a kastasyon nan Washington
6 etid pou Kansè pwostat rezistan a kastasyon ap chèche patisipan nan sit nan Washington.
Vil nan Washington
Tèks ofisyèl etid la (Anglè)
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
- Fred Hutch Cancer Center Sloan Clinic 2, Seattle
- Fred Hutchinson Cancer Research Center, Seattle
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07225946A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- VA Puget Sound Healthcare System, Seattle
- Fred Hutchinson Cancer Research Center, Seattle
- University of Washington, Seattle
Ap rekriteFaz 3
Laj 18 ak plis · Gason · Mizajou Sep 25, 2026 · NCT07164443A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
- Fred Hutchinson Cancer Center ( Site 0013), Seattle
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT06863272Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
- Investigational Site Number: 400, Seattle
Ap rekriteFaz 1
Laj 18 ak plis · Gason · Mizajou Sep 10, 2026 · NCT05997615A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Swedish Cancer Institute, Seattle
- Fred Hutchinson Cancer Center, Seattle
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT04104776A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
- Fred Hutchinson Cancer Center, Seattle
Ap rekriteFaz 1
Laj 18 ak plis · Gason · Mizajou Aug 10, 2026 · NCT06067841Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.